Premium
Evaluation of resveratrol and N ‐acetylcysteine for cancer chemoprevention in a Fanconi anemia murine model
Author(s) -
Zhang QingShuo,
MarquezLoza Laura,
Sheehan Andrea M.,
WatanabeSmith Kevin,
Eaton Laura,
Benedetti Eric,
Major Angela,
Schubert Kathryn,
Deater Matthew,
Joseph Eric,
Grompe Markus
Publication year - 2014
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.24780
Subject(s) - fanconi anemia , fancd2 , medicine , resveratrol , acetylcysteine , cancer research , anemia , cancer , bone marrow failure , bone marrow , pharmacology , immunology , dna repair , biochemistry , biology , antioxidant , dna , genetics , haematopoiesis , stem cell
Fanconi anemia (FA) patients suffer from progressive bone marrow failure and often develop cancers. Previous studies showed that antioxidants tempol and resveratrol (RV) delayed tumor onset and reduced hematologic defects in FA murine models, respectively. Here we tested whether antioxidants N ‐acetylcysteine (NAC) or RV could delay cancer in tumor prone Fancd2 −/− /Trp53 +/− mice. Unlike tempol, neither compound had any significant chemopreventive effect in this model. We conclude that not all anti‐oxidants are chemopreventive in FA. In addition, when given to Fancd2 −/− mice, NAC helped maintain Fancd2 −/− KSL cells in quiescence while tempol did not. The mechanisms behind the different actions of these antioxidants await further investigation. Pediatr Blood Cancer 2014;61:740–742. © 2013 Wiley Periodicals, Inc.